MAT2A and neoplasm: Due to the recent lack of appropriate MAT2A inhibitors, cycloleucine as a substrate-competitive inhibitor with low affinity to MAT2A, has been used to block MAT2A non-specifically in T-cell leukemia and other tumor entities with unclear effects and also affecting other essential pathways [13,44].